Agilent completes Proscia acquisition for $240 million upfront to expand AI-enabled digital pathology
Agilent Technologies has completed its acquisition of Proscia for $240 million upfront, adding digital-pathology software and AI-enabled diagnostic capabilities to its life sciences and diagnostics business.
The acquisition completed on 4 November 2026 brings Proscia's vendor-agnostic digital-pathology platform and FDA-cleared primary-diagnosis software capabilities into Agilent's Life Sciences and Diagnostics Markets Group, alongside Agilent's existing pathology instruments and reagents.
Agilent paid $240 million in cash at closing with up to $30 million in additional performance-based consideration, making this a completed transaction distinct from the original 13 October agreement announcement and expanding its capabilities in clinical diagnostics, biomarker research and companion-diagnostic development.
Field | Content |
Article Type | Deals |
Acquirer | Agilent Technologies |
Acquired Company | Proscia |
Deal Type | Completed digital-pathology software acquisition |
Completion Date | 4 November 2026 |
Original Agreement Announcement | 13 October 2026 |
Transaction Status | Completed |
Upfront Cash Consideration | $240 million paid at closing |
Additional Contingent Consideration | Up to $30 million |
Maximum Potential Consideration | Up to $270 million |
Contingent Payment Basis | Performance-based |
Acquiring Business Unit | Life Sciences and Diagnostics Markets Group |
Acquired Technology | Digital-pathology software platform |
Platform Characteristics | Vendor-agnostic |
Regulatory Capability | FDA-cleared primary-diagnosis software capabilities |
Technology Focus | Digital pathology and AI-enabled pathology workflows |
Clinical Application | Clinical pathology and diagnostic workflows |
Research Application | Biomarker research |
Additional Application | Companion-diagnostic development |
Agilent Existing Capabilities | Pathology instrumentation and reagents |
Integration Focus | Combine Proscia software with Agilent's existing pathology technologies |
Geographic Scope | Not specified in supplied summary |
What Happened | Agilent completed its previously announced acquisition of Proscia. |
Why It Matters | The acquisition expands Agilent's capabilities in digital pathology and software-supported clinical diagnostics. |
Strategic Rationale | Integrate digital-pathology software and AI-enabled workflows with Agilent's established diagnostic instrumentation and reagent portfolio. |
Financial Clarification | The $240 million closing payment is separate from up to $30 million in contingent performance consideration. |
Transaction Distinction | Newly completed acquisition rather than a repeat of the original agreement announcement. |
Key Takeaway | Agilent has acquired Proscia for $240 million upfront, with a potential additional $30 million contingent payment. |
What to Watch | Software integration, pathology workflow adoption, companion-diagnostic applications and achievement of contingent payment conditions. |
Primary Source | Agilent Technologies |
Primary Source URL | https://www.agilent.com/about/newsroom/presrel/2026/04nov-gp26022.html |
Relevant Date | 4 November 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
留言